Biotech News

LIXTE Joins Russell Microcap Index

Lixte Biotechnology Holdings (LIXT)Lixte Biotechnology Holdings2026-06-26 12:30 ESTCompany update

BOCA RATON, Fla., June 26, 2026 (GLOBE NEWSWIRE) -- LIXTE Biotechnology Holdings, Inc. (“LIXTE” or the “Company”) (Nasdaq: LIXT), today announced its inclusion in the Russell Microcap ® Index, effective after the close of the U.S. equity markets on June 26, 2026, as part of the annual Russell U.S. Indexes reconstitution. The reconstituted indexes will take effect at the opening of trading on Monday, June 29, 2026.

LIXTE’s inclusion in the Russell Microcap Index represents an important milestone for the Company and reflects the significant progress we have made over the past year,” said Geordan Pursglove, Chief Executive Officer of LIXTE. “Under our new leadership team and strategic direction, we have successfully transformed the Company and enhanced shareholder value. We believe membership in the Russell Microcap Index will increase our visibility among institutional investors, broaden awareness of our growth strategy, and support our efforts to build a leading platform focused on AI energy infrastructure equipment and services. This recognition comes at a pivotal time as demand for power and infrastructure solutions continues to accelerate alongside the expansion of AI and hyperscale data centers.”

The Russell U.S. Indexes are among the most widely recognized benchmarks for institutional investors and investment managers. Membership in the Russell Microcap Index provides exposure to investment products and funds that benchmark their performance against Russell indexes.

The Russell Microcap Index measures the performance of smaller publicly traded U.S. companies and serves as a widely followed benchmark for active and passive microcap investment strategies. Russell indexes are reconstituted annually to reflect changes in the U.S. equity market and to ensure that growing companies are appropriately represented.

About LIXTE

LIXTE Biotechnology Holdings, Inc. is a holding company that historically focused on the development of innovative cancer therapies and medical technologies. The Company is currently executing a strategic transformation into an AI energy infrastructure equipment and services platform focused on supporting the rapidly growing power and infrastructure requirements of artificial intelligence, cloud computing, and hyperscale data center operators. Through this transition, LIXTE aims to capitalize on the accelerating demand for reliable, scalable, and efficient energy infrastructure solutions driven by the global expansion of AI.

For more information about LIXTE, info@lixte.com , contact:

General Phone: (631) 830-7092; Investor Phone: (888) 289-5533 or PondelWilkinson Inc. Investor Relations, [email protected] Roger Pondel: (310) 279-5965; Laurie Berman: (310) 279-5962

Source: Lixte Biotechnology Holdings, Inc. Released June 26, 2026

Open original release

Related news

LIXTLixte Biotechnology Holdings2026-07-15 12:30 EST

NOMAD Power Solutions Strengthens Subsidiary Executive Leadership

LIXTLixte Biotechnology Holdings2026-07-08 12:30 EST

NOMAD Increases Voyager Fleet Energy Storage by up to 56%, Bringing Eagle and Falcon to 2.025 MWh

LIXTLixte Biotechnology Holdings2026-07-06 12:30 EST

LIXTE Completes Corporate Name Change to NOMAD Power Solutions, Inc.; To Begin Trading Under New Nasdaq Symbol NMAD

LIXTLixte Biotechnology Holdings2026-07-02 12:30 EST

LIXTE COMPLETES MERGER WITH NOMAD TRANSPORTABLE POWER SYSTEMS

LIXTLixte Biotechnology Holdings2026-07-02 12:30 EST

LIXTE COMPLETES MERGER WITH NOMAD TRANSPORTABLE POWER SYSTEMS

LIXTLixte Biotechnology Holdings2026-06-25 13:46 EST

LIXTE Biotechnology Provides Update on NOMAD Acquisition; Transaction Expected to Close On or About July 1, 2026

LIXTLixte Biotechnology Holdings2026-06-25 13:46 EST

LIXTE Biotechnology to Acquire NOMAD Transportable Power Systems, the Market Leader in Mobile, Utility-Grade Battery Energy Storage Systems (BESS)

LIXTLixte Biotechnology Holdings2026-06-25 13:46 EST

LIXTE Biotechnology Announces $16,566,027 Registered Direct Offering Priced at the Market Under Nasdaq Rules, Strengthening Balance Sheet for Next Phase of Strategic Growth

LIXTLixte Biotechnology Holdings2026-06-25 13:46 EST

LIXTE Biotechnology Announces Strategic Transformation into AI Energy Infrastructure Equipment & Services; Stuart D. Porter, Founder of Denham Capital, to Join Board of Directors

LIXTLixte Biotechnology Holdings2026-06-25 13:46 EST

LIXTE Biotechnology Files First Quarter 2026 Quarterly Report on Form 10-Q; Provides Operational Progress Update

Lixte Biotechnology Holdings

Lixte Biotechnology Holdings is a biopharmaceutical company focused on pipeline execution and catalyst-driven growth, with investors tracking how data, regulatory milestones, and launch timing reshape the investment case.

Recent company news

Stock data

Close
7.21 USD
Market cap
Exchange
NASDAQ
Sector
Biotechnology
Location
United States